Similar articles for PMID: 10188062

Year	Number of Results
1956	1
1957	2
1958	1
1969	1
1977	1
1987	1
1989	2
1990	5
1991	1
1992	2
1993	2
1994	1
1995	1
1996	3
1997	1
1998	1
1999	3
2000	5
2001	4
2002	4
2003	3
2004	4
2005	5
2006	5
2007	5
2008	2
2009	1
2010	2
2011	1
2012	1
2013	1
2014	2
2018	1
2019	1
2023	1
2024	0

1

Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma.

Deshpande H, Dutcher JP, Novik Y, Oleksowicz L. Deshpande H, et al. Cancer J Sci Am. 1999 Jan-Feb;5(1):52-3. Cancer J Sci Am. 1999. PMID: 10188062 No abstract available.

2

Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.

McDermott DF, Atkins MB. McDermott DF, et al. Semin Oncol. 2006 Oct;33(5):583-7. doi: 10.1053/j.seminoncol.2006.06.004. Semin Oncol. 2006. PMID: 17045087 Review.

3

Medeiros BC, Kogel KE, Kane MA. Medeiros BC, et al. Transfus Apher Sci. 2003 Aug;29(1):25-7. doi: 10.1016/S1473-0502(03)00094-6. Transfus Apher Sci. 2003. PMID: 12877889

4

Myositis following treatment with high dose interleukin-2 for malignancy.

Finger DR, Plotz PH, Heywood G. Finger DR, et al. J Rheumatol. 1995 Nov;22(11):2188. J Rheumatol. 1995. PMID: 8596171 No abstract available.

5

High-dose interleukin-2 in metastatic renal cell carcinoma.

Fernández-Rodríguez R, de Argumedo GL, Mañé JM, Muñoz A, Ferreiro J, Fuente N, López-Vivanco G. Fernández-Rodríguez R, et al. J Clin Oncol. 2005 Sep 20;23(27):6797-8; author reply 6798-9. doi: 10.1200/JCO.2005.02.1709. J Clin Oncol. 2005. PMID: 16170190 No abstract available.

6

Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.

van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MA. van der Vliet HJ, et al. Clin Cancer Res. 2007 Apr 1;13(7):2100-8. doi: 10.1158/1078-0432.CCR-06-1662. Clin Cancer Res. 2007. PMID: 17404092 Clinical Trial.

7

Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.

Hosokawa Y, Kishino T, Ono T, Oyama N, Hayashi K, Momose H. Hosokawa Y, et al. Int J Urol. 2004 Oct;11(10):906-8. doi: 10.1111/j.1442-2042.2004.00914.x. Int J Urol. 2004. PMID: 15479299 Free article.

8

Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.

van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH. van Herpen CM, et al. Br J Cancer. 2000 Feb;82(4):772-6. doi: 10.1054/bjoc.1999.0997. Br J Cancer. 2000. PMID: 10732744 Free PMC article. Clinical Trial.

9

High-dose interleukin-2 is an intensive treatment regardless of the venue of administration.

Schwartzentruber DJ. Schwartzentruber DJ. Cancer J. 2001 Mar-Apr;7(2):103-4. Cancer J. 2001. PMID: 11324761 No abstract available.

10

A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.

Lissoni P, Rovelli F, Baiocco N, Tangini G, Fumagalli L. Lissoni P, et al. Anticancer Res. 2001 Jan-Feb;21(1B):777-9. Anticancer Res. 2001. PMID: 11299843 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

76 results

Results by year